The two EGFR‐positive advanced lung adenocarcinoma never smoker female patients (58 years old, T4N2M1, L858R; 61 years old, T2N3M1, 19Del) were administered gefitinib and subsequent osimertinib. This evidence concerns the gene EGFR and lung adenocarcinoma.